Virtual09/06/2021

EHA2021 Virtual Congress

European Hematology Association

Join us for the virtual edition of the 26th Congress of the European Hematology Association

Octapharma is supporting the #EHA2021 Virtual Congress to keep the scientific community up to date on treating patients with secondary immunodeficiencies associated with hematological malignancies.

Update in Hematology

Monday, 14 June 2021 18:00 – 19:30 CET

Live welcome and introduction

All

Antibody deficiency and infectious complications in CLL: current knowledge and future perspective

Anthony R. Mato

Memorial Sloan Kettering Cancer Institute, USA

CAR T-cell therapy: infection risk and hypogammaglobulinaemia

Joshua A. Hill

Fred Hutchinson Cancer Research Center, USA

Are Immunologists from Mars and Haematologists from Venus? The road to consensus in Secondary Antibody Deficiency

Stephen Jolles

University Hospital of Wales, UK

Management of CLL patients in the era of Covid-19 pandemic

Paolo Ghia

Vita-Salute San Raffaele University of Milan, Italy

Live panel discussion - Q&A

All

On demand available now

Meet our speakers

Anthony Mato, MD, MSCE - Memorial Sloan Kettering Cancer Institute, USA

PROFESSIONAL PROFILE

Joshua A. Hill, M.D. Fred Hutchinson Cancer Research Center, USA

Professional profile

Stephen Jolles, University Hospital of Wales, UK

Professional profile

Paolo Ghia, Vita-Salute San Raffaele University of Milan, Italy

professional profile

Visit our website to learn more about SID

"Secondary immunodeficiencies have been a major concern in hematological malignancies. We need to remain very careful with the risk of infection.", says Dr. Anne Quinquenel (Reims, France).